Atraric acid

Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases[1][2].

Product Specifications

CAS Number

[4707-47-5]

Product Name Alternative

Methyl atrarate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Androgen Receptor; NF-κB; NO Synthase; p38 MAPK

Type

Natural Products

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/atraric-acid.html

Concentration

10mM

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OC)C1=C(C)C=C(O)C(C)=C1O

Molecular Formula

C10H12O4

Molecular Weight

196.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Roell D, Baniahmad A. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol Cell Endocrinol. 2011 Jan 30;332 (1-2) :1-8.|[2]Papaioannou M, et al. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J Cell Mol Med. 2009 Aug;13 (8B) :2210-2223.